Meril Life Sciences comes late to aortic valves
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
Veracyte’s nasal lung cancer test results raise questions
Amid the sea of lung cancer blood test developers, one company has nosed out a different approach.
Hologic burns its aesthetics unit
Cynosure’s technology seems to have been better at destroying value than it was at destroying fat – Hologic has sold the business for a tenth of the purchase price.
Who will buy Qiagen?
The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
Medtech venture investors wait longer for an exit
The period between a device company’s foundation and its acquisition has lengthened over the past few years, and currently stands at more than a decade.
The next orthopaedics megamerger
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
Wright and Stryker embark on a joints venture
Stryker’s scale-building efforts have been notable over the past few years, and at $4.7bn this is its largest-ever deal.
One step forward, two steps back for prescription apps
Ironwood signs up with the leading prescription app developer, but Pear is not to everyone’s taste.
Another robot deal for J&J shows up lack of Verb results
Johnson & Johnson is going in hard on robotics, but its first big move here has still not paid off.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.